Absci Corp (ABSI) stock
Close on Nov 12, 2026Market cap $1.57BP/E –Yield –
Absci Corp saw revenue fall 47.2% to $1.49M over the twelve months to Sep 30, 2026. Free cash flow was -$112.46M. At the latest close the market valued the company at $1.57B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.57B
- P/E ratio
- –
- Price to sales
- 1054.26
- Price to book
- 7.17
- Dividend yield
- –
- Free cash flow yield
- -7.17%
Fundamentals
- Revenue
- $1.49M
- Net income
- -$125.67M
- EPS, diluted
- -$0.79
- Free cash flow
- -$112.46M
- Book value per share
- $1.27
- Diluted shares
- 172M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $10.12
- Open
- $9.39
- Day's range
- $8.96 – $9.94
- Volume
- 4,918,283
- Average volume (20 days)
- 4,108,451
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 2.22
- 52-week range
- $2.24 – $12.54
- RSI (14 days)
- 50.7
- Volatility (1 year)
- 105.7%
- Relative volume
- 1.49×
- WACC
- 16.0%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABSI | S&P 500 | Difference | ABSI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.5% | -2.7% | −2.8 pts | ||
| 3 months | -3.8% | -1.7% | −2.1 pts | ||
| Year to date | +161.7% | +11.9% | +149.9 pts | ||
| 1 year | +168.7% | +12.0% | +156.7 pts | ||
| 3 years | +619.3% | +78.2% | +541.1 pts | +93.0% | +21.2% |
| 5 years | -18.3% | +73.2% | −91.5 pts | -4.0% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Absci filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
About Absci
Services-Commercial Physical & Biological Research
Absci Corporation is a clinical-stage biopharmaceutical company that designs and develops differentiated antibody therapeutics using an artificial intelligence platform integrated with laboratory testing. Its operations include an internal pipeline of drug candidates as well as partnered discovery programs. The company’s lead investigational therapeutic, ABS-201, targets prolactin receptor signaling to treat androgenetic alopecia and endometriosis. Absci also develops additional antibody programs, such as ABS-101, alongside early-stage oncology and immunology candidates. The firm collaborates with external pharmaceutical and biotechnology companies, offering AI-guided antibody discovery, de novo protein design, and lead optimization services to support partners' development pipelines.
Company profile, executives and historyAbsci stock: common questions
What is Absci's stock price?
ABSI closed at $9.13 on Nov 12, 2026, down 9.73% on the day. Over the past 52 weeks it traded between $2.24 and $12.54.
What is Absci's market cap?
Absci was worth $1.57B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ABSI's P/E ratio?
Absci lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.79), so it has no meaningful P/E ratio.
How much revenue does Absci make?
Absci reported revenue of $1.49M for the twelve months to Sep 30, 2026, down 47.2% from a year earlier.
Does Absci pay a dividend?
No. Absci has not paid a cash dividend over the last twelve months.
When does Absci report earnings next?
Absci's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has ABSI stock performed over the past year?
Including dividends, ABSI returned +168.7% over the past year, against +12.0% for the S&P 500.
How many ABSI shares are sold short?
36M shares were sold short at the latest FINRA report, 24.71% of the float, or 9.1 days of average trading volume.
Who are Absci's competitors?
Companies most similar to Absci by business, industry and size include ONMD, BIAF, IBIO, OABI, AIDX.
See a number that looks wrong?